Cargando…
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
Multiple myeloma (MM) is a malignant disease of the plasma cells representing approximately 10% of all hemato-oncological diseases. Detection of the disease is most probable at around 65 years of age, and the average survival of patients is estimated to be 5–10 years, specifically due to frequent re...
Autores principales: | Weiser Drozdkova, Denisa, Smesny Trtkova, Katerina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293232/ https://www.ncbi.nlm.nih.gov/pubmed/34205025 http://dx.doi.org/10.3390/curroncol28030193 |
Ejemplares similares
-
The epigenetic impact of suberohydroxamic acid and 5-Aza-2′-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression
por: Smesny Trtkova, Katerina, et al.
Publicado: (2022) -
Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma
por: Hurník, Pavel, et al.
Publicado: (2022) -
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs—disulfiram and ritonavir
por: Kast, Richard E
Publicado: (2015) -
Disulfiram—Mitigating Unintended Effects
por: Grout, Martha M., et al.
Publicado: (2023) -
Disulfiram: Mechanisms, Applications, and Challenges
por: Lanz, Jenna, et al.
Publicado: (2023)